Celldex Therapeutics Stock Rating Reaffirmed by Wedbush (CLDX)
Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “outperform” rating restated by analysts at Wedbush in a research report issued to clients and investors on Wednesday, ARN reports. They currently have a $25.00 price objective on the stock, down from their previous price objective of $35.00. Wedbush’s price target suggests a potential upside of 4.60% from the company’s current price.
A number of other analysts have also recently weighed in on CLDX. Analysts at Oppenheimer raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $16.00 to $25.00 in a research note to investors on Wednesday, August 7th. Separately, analysts at Leerink Swann raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $18.00 to $28.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at Jefferies Group raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $19.00 to $25.00 in a research note to investors on Wednesday, August 7th.
Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $25.50.
Shares of Celldex Therapeutics (NASDAQ:CLDX) traded up 6.70% during mid-day trading on Wednesday, hitting $23.90. 2,273,038 shares of the company’s stock traded hands. Celldex Therapeutics has a 1-year low of $5.02 and a 1-year high of $23.92. The stock has a 50-day moving average of $20.96 and a 200-day moving average of $15.11. The company’s market cap is $1.936 billion.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.24) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.22) by $0.02. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was down 51.7% on a year-over-year basis. On average, analysts predict that Celldex Therapeutics will post $-0.96 earnings per share for the current fiscal year.
Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.